T cells are among the three immune cell types that communicate antigen receptors. help revitalizing T cell growth and transferring the activated immune cells into the hosts, that target against tumor cells or stimulate immune response to remove tumor cells [1C3]. There are two main categories of T lymphocytes: and T cells. The difference of these two types of T cells is definitely that they indicated different cell surface antigen receptors . The majority of T cells identify antigenic peptides with major histocompatibility complex (MHC) class I or class II. In the peripheral blood, T cells account for about 95%, while T cells contribute to only 5% of total CD3+ cells . Cells with the cell surface receptors generally communicate CD4 or CD8 lineage markers. Most of the T cells belong to helper or cytotoxic/effector subsets [7, 8]. In contrast, T cells do not usually express CD4 or CD8 lineage markers, and they do not require standard MHC antigen demonstration . T cells have the capacity of secreting abundant cytokines. They exert potent cytotoxicity against a wide range of malignancies [9C11]. Consequently, T cells have become the attractive effector cells for malignancy immunotherapy. This review will discuss the classification and characteristics of T cells, the functions of, T cells in anti-cancer therapy, the progress in clinical software using T cells and the prospect of developmental direction of T cells in the future. CLASSIFICATION OF T CELLS Human being T cells are subdivided into V1, V2 and V3 T cells based on their surface antigen. They are a group of unconventional T cells . Typically, about 50% to 75% of T lymphocytes in peripheral-blood communicate V2 chain, and co-express V9 chain. These cells are named V9V2 T cells. V9V2 T cells present only in humans and nonhuman primates  and contribute to 1% to 10% of T cells in the peripheral blood of healthy human being [14, Ace2 15]. Activated V2 T cells communicate cell adhesion molecules, such as CD86, CD80 and MHC-II. They display the characteristics of professional antigen showing cells. V9V2 T cells have the unique feature of realizing non-peptidic phosphoantigens. These cells proliferate vigorously in response to activation of microbial or synthetic phosphoantigens . They play a critical function in anti-infection immunity and anti-tumor security [18, 19]. Activated V9V2 T cells exhibit granulysin, perforin, Fas/Fas ligand (FasL), granzyme-A and B,to eliminate the asexual levels of P.falciparum and inhibit the development of intraerythrocytic levels of P.falciparum within the bloodstream . Furthermore, turned on V9V2 4E1RCat T cells exhibit TGF-, IL-10 and IL-4. They inhibit T cell proliferation 4E1RCat  also. The next subset of T cells gets the V1 string. V1+ T cells tend to be more widespread in tissue than in the peripheral bloodstream. A lot of the tissue-associated T cells contain the function of defending against epithelial malignancies [22C24]. V1 string is prominent within the intraepithelial level of mucosal surface area . V1+ T cells defend epithelial tissues integrity against cell change, injury or an infection [26, 27]. Both V2 and V1 T cell subsets possess almost equal levels of NKG2D+ cells and CD6+ cells.. The V1 subset provides even more IFN–producing cells and Compact disc27+Compact disc45RA- cells compared to the V2 subset . Furthermore, the peripheral V2 could be extended by phosphoantigens. The anti- Ab is really a potent stimulus which could expand both V2 and V1 subsets . The anti-CD3 Ab [28, 29] 4E1RCat or concanavalin A [22, 28] could also be used to broaden both V1 and V2 subsets. Besides V1 and V2 cells, there’s a really small subset of.